Open Journal of Gastroenterology and Hepatology


Gallic acid produces hepatoprotection by modulating EGFR expression and phosphorylation in induced preneoplastic liver foci in rats

Research Article of Open Journal of Gastroenterology and Hepatology Gallic acid produces hepatoprotection by modulating EGFR expression and phosphorylation in induced preneoplastic liver foci in rats Jorge Reyes-Esparza M.D. and Ph.D.1, Rebeca Escutia-Gutiérrez M. Pharm. 1, Francisco Garcia-Vázquez  Q.B.P. 2, Lourdes Rodríguez-Fragoso M.D. and Ph. D. 1 1Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca 62210, Mexico. 2Instituto Nacional de Pediatria, Mexico City, Mexico. The purpose of this study was to analyze the role of gallic acid as liver protector and identify its role in the regulation of EGFR expression and phosphorylation in induced preneoplastic liver lesions in rats. Male Wistar rats were randomly divided into four groups. (1) Control; (2) animals receiving gallic acid (AG) 50 mg/kg v.o. for 8 weeks; (3) animals with preneoplasia (P)  induced by a single dose of diethylnitrosamine 200 mg/kg i.p. (DEN) and two weeks after a single dose of carbon tetrachloride 2 mL/kg i.p. (CCl4); and (4) animals with preneoplasia treated with GA during 8 weeks.  In order to evaluate GA hepatoprotection on preneoplastic lesions, we performed histological examination of liver tissue using H&E staining as well as an immunohistochemical analysis for PCNA. To evaluate the effect of GA on EGFR expression and phosphorylation, we performed an immunohistochemical and western blot analysis. The results indicated that GA significantly decreased EGFR expression and pY1068 EGFR phosphorylation in animals with preneoplastic lesions. GA significantly decreased PCNA expression in animals with preneoplastic lesions, suggesting it may work as an antiproliferative agent. Additionally, GA improved the architecture and organization of liver tissue and significantly decreased serum AST, ALT and FA, which are indicators of hepatocellular damage. By histopathological and immunohistochemical analysis we demonstrated an improvement in liver morphology, a reduction of preneoplastic liver foci and a reduction of cell proliferation, as well as an improvement ...

Effectiveness and safety of glecaprevir and pibrentasvir for hemodialysis patients with hepatitis C virus infection at a single center

Research Article of Open Journal of Gastroenterology and Hepatology Effectiveness and safety of glecaprevir and pibrentasvir for hemodialysis patients with hepatitis C virus infection at a single center Naoki Hotta Department of Hepatology, Masuko Memorial Hospital Background/Aims: Glecaprevir/pibrentasvir (GLE/PIB) is a pan-genotypic regimen for the treatment of hepatitis B virus (HCV) infection. GLE and PIB are direct acting antiviral (DAA) agents that can be used for patients with chronic renal failure who are on hemodialysis (HD) and those with HCV genotype 2 infections. Here, we report the usefulness and safety of GLE/PIB in 13 hemodialysis (HD) patients with HCV infection. Material and Methods: The subjects comprised patients with genotype 1 and 2 (six each) and one unknown genotype patient in whom GLE/PIB therapy was introduced by December 2018. The mean age was 69.2 (59-78) years (seven men and six women). The mean HCV RNA amount prior to treatment initiation was 4.81 (2.1-6.5). The administration periods were 8 and 12 weeks (n = 9 and 4, respectively). Results: Twelve patients received all the doses orally while an increase in total bilirubin (T-BIL) caused administration to be discontinued in one patient. HCV RNA at week 4 after treatment initiation became undetectable in 11 (91.6%) of the 12 patients. All patients achieved rapid viral response (RVR). Concerning adverse effects, although itching occurred in three (25%) patients, the symptom improved following administration of oral medication and the treatment was able to be continued. Conclusion: The results suggest that GLE/PIB can also be safely administered to HD patients. However, the usefulness and safety need to be further studied by examining more cases. Keywords: hepatitis C, hemodialysis ...

Silent but Treacherous: A Case Report of Silent Perforated Peptic Ulcer in an Elderly Patient

Case Report of Open Journal of Gastroenterology and Hepatology Silent but Treacherous: A Case Report of Silent Perforated Peptic Ulcer in an Elderly Patient Lakis Remi M.D., Hallal Mahmoud M.D.*, Hijazi Ghadir M.D., Zorkot Wael M.D., Ramadan Ahmad M.D., Mansour Bassam M.D. AlZahraa Hospital University Medical Center (Zhumc) ,Beirut, Lebanon Peptic ulcer disease (PUD) is one of the most common gastroduodenal disorders. Its prevalence has been decreasing over recent years. It has multiple complications, one of which is the life-threatening perforation. The latter usually present in a dramatic clinical picture and often necessitate an emergent surgical approach. A silent gastric perforation, however, is one of the rare conditions in the clinical practice which makes the diagnosis more challenging. We describe a case of silent perforated peptic ulcer complicated with septic shock and treated by surgery. This report highlights the wide spectrum of the clinical presentations of the peptic ulcer disease. Keywords: Peptic ulcer disease (PUD), silent gastric perforation, life-threatening perforation ,septic shock ...

Study the Role of Combined M2-Pyruvate kinase, Calprotectin and Occult Blood Test as Fecal Biomarkers for Early Detection of Colorectal Cancer

Research Article of Open Journal of Gastroenterology and Hepatology Study the Role of Combined M2-Pyruvate kinase, Calprotectin and Occult Blood Test as Fecal Biomarkers for Early Detection of Colorectal Cancer Atef Abo El-Soud Ali1, Mohamed Gamal El Helbawy2, Huda Saad Elmehily3, Emad Mohamed Salem4, Ahmed Abo Zaid Ahmed5 1Proffessor of Tropical Medicine(Menoufia University), 2Lecturer of clinical Pathology(Menoufia University) 3Tropical Medicine Department (Menoufia University), 4Head of Gastroenterology department of NJCH ( New Jeddah Clinic Hospital ) KSA, 5Lecturer of Tropical Medicine(Menoufia University) Background and study aim: One of the main requirements of biomarkers for detecting CRC is that it must allow detection of the disease at earlier stages. The current study is designed to investigate the role of combined M2-Pyruvate kinase, Calprotectin, and Fecal occult blood test measurements as fecal diagnostic biomarkers for early detection of colorectal cancer. Patients & Methods: Total number of 72 subjects (48 patients and 24 healthy controls) were included in the study. Patients with cancer colon and patients with organic non-malignant colorectal lesions were recruited from Oncology and Gastroenterology Outpatient Clinics and Inpatient Department Menoufia University Hospital. Results: There was a highly significant difference between studied groups regarding age and gender (P> 0.001), cancer colon was higher among old age (mean ± SD is 58.96±6.3) and males (70.8%), There was a highly significant difference between studied groups regarding Hb, CRP and ESR (P >0.001); lowest Hb level was detected in cancer group (8.7±1.7). On the other hands highest CRP and ESR levels were in cancer group (7.29±4.47) and (14.71±6.19) respectively. There was a significant difference between studied groups regarding platelets (P >0.05); lowest platelet number was detected in cancer group (272.4±66.9). There was non-significant difference between studied groups regarding WBCs (P <0.05); highest WBCs number was detected in cancer group (8.05±2.3), There was a highly significant ...

Dr. Mohammed Naeem
Chair, Patient Safety Reporting/Consultant Pediatric Intensivist/ Head PICU (A)/ Assistant Professor, Dept. of Pediatrics. Ministry National Guard Health Affairs Riyadh, Saudi Arabia

Dr Toru Ishikawa
Gastroenterology, Saiseikai Niigata Daini Hospital

Dr. George Paraskevas
Associate Professor of Anatomy Orthopedic Surgeon, Department of AnatomyMedical School, Aristotle University of Thessaloniki, Post Box: 300, Post Code: 54124, Thessaloniki, Greece

Dr. Mahaboob Vali Shaik
Assistant Professor/Senior Scientist, Department of Genetics & stem cell Research, Narayana Medical College & Hospitals

Dr. Ifeadike Chigozie Ozoemena
Associate Professor, Department of Community Medicine, Faculty of Medicine, Nnamdi Azikiwe University

Dr. Eduardo de Moura GH
Professor, niversity of São Paulo School of Medicine, São Paulo, Brazil

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1.Gomes, K.K.L; Lima, A.A.F. Living Style of Diabetic Patients Type.Open Journal of Gastroenterology and Hepatology, 2018, 1:5. DOI:10.28933/ojgh-2018-05-1005

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access

Open Journal of Gastroenterology and Hepatology is a peer reviewed open access journal publishing research manuscripts, review articles, editorials, letters to the editor in Gastroenterology and Hepatology  (Indexing information).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

Open Journal of Gastroenterology and Hepatology LOGO1

Loading